ATE189814T1 - Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung - Google Patents

Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung

Info

Publication number
ATE189814T1
ATE189814T1 AT97106079T AT97106079T ATE189814T1 AT E189814 T1 ATE189814 T1 AT E189814T1 AT 97106079 T AT97106079 T AT 97106079T AT 97106079 T AT97106079 T AT 97106079T AT E189814 T1 ATE189814 T1 AT E189814T1
Authority
AT
Austria
Prior art keywords
group
substituted
alkyl group
halogen
hydrogen atom
Prior art date
Application number
AT97106079T
Other languages
English (en)
Inventor
Mitsuru Shiraishi
Tsuyoshi Maekawa
Toshifumi Watanabe
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE189814T1 publication Critical patent/ATE189814T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT97106079T 1996-04-15 1997-04-14 Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung ATE189814T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9290496 1996-04-15

Publications (1)

Publication Number Publication Date
ATE189814T1 true ATE189814T1 (de) 2000-03-15

Family

ID=14067477

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97106079T ATE189814T1 (de) 1996-04-15 1997-04-14 Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung

Country Status (5)

Country Link
US (1) US5891895A (de)
EP (1) EP0802187B1 (de)
AT (1) ATE189814T1 (de)
CA (1) CA2202578A1 (de)
DE (1) DE69701298T2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ES2275931T5 (es) * 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CA2475818C (en) * 2002-02-11 2011-07-19 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
CN100410251C (zh) * 2003-06-26 2008-08-13 诺瓦提斯公司 可用于制备某些抗菌n-甲酰基羟胺的中间体的制备方法
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
WO2005110994A2 (en) * 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2006084031A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH350461A (de) * 1957-12-06 1960-11-30 Ciba Geigy Verwendung von Oxyketonen zum Schutze gegen ultraviolette Strahlung
JPS49119718A (de) * 1973-03-23 1974-11-15
CH605925A5 (de) * 1974-08-30 1978-10-13 Ciba Geigy Ag
US4297359A (en) * 1978-07-25 1981-10-27 Acf Chemiefarma Nv Anti-ulcer compositions containing certain pyridyl oxime ethers
US4798841A (en) * 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
DK270488D0 (da) * 1988-05-18 1988-05-18 Novo Industri As Hidtil ukendte o-substituerede ketoximer
JP2765876B2 (ja) * 1988-10-24 1998-06-18 科研製薬株式会社 ピリジルケトオキシムエーテル誘導体
EP0388682A1 (de) * 1989-03-15 1990-09-26 Bayer Ag Substituierte Heteroarylphenylether, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
FR2644456B1 (fr) * 1989-03-17 1991-07-05 Rhone Poulenc Sante Nouveaux derives du 1h, 3h-pyrrolo(1,2-c)thiazolecarboxamide-7, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0499767A (ja) * 1990-08-20 1992-03-31 Nippon Bayeragrochem Kk 3―ベンゾイルピリジン0―ベンジルオキシム類の除草剤としての利用
EP0637297B1 (de) * 1992-04-22 2000-08-23 Ligand Pharmaceuticals, Inc. Retinoid-x rezeptor selektive verbindungen
TW266206B (de) * 1993-04-28 1995-12-21 Takeda Pharm Industry Co Ltd
JPH08175994A (ja) * 1994-10-27 1996-07-09 Takeda Chem Ind Ltd 脂質代謝改善剤

Also Published As

Publication number Publication date
EP0802187A1 (de) 1997-10-22
CA2202578A1 (en) 1997-10-15
US5891895A (en) 1999-04-06
DE69701298T2 (de) 2000-10-05
DE69701298D1 (de) 2000-03-23
EP0802187B1 (de) 2000-02-16

Similar Documents

Publication Publication Date Title
DE69701298D1 (de) Hydroxypyridin-Derivate, ihre Herstellung und ihre pharmazeutische Verwendung
ATE180468T1 (de) Anthranilsäure derivate
EP1035123A4 (de) Neue heterozyklische verbindungen
EE04373B1 (et) Fungitsiidsed trifluorometüülalküülaminotriasolopürimidiinid
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
DE3782883D1 (de) Pyridincarboxamid-derivate und ihre verwendung als fungizides mittel.
TR200002606T2 (tr) Benzen-sülfonamit türevleri ve ilaç olarak kullanımları.
ATE74132T1 (de) Imid-derivate, ihre herstellung und ihre verwendung.
DK0887344T3 (da) Quinoliner og quinazoliner, som er nyttige ved terapi
ATE89556T1 (de) Naphthalenverbindungen und antiallergische und antiinflammatorische pharmazeutische mittel.
ATE199253T1 (de) Antidepressiv wirkende 3-halophenylpiperazinyl- propylderivate von substituierten triazolonen und triazoldionen
DE3767778D1 (de) Entzuendung verhindernde und allergie heilende mittel.
ATE92489T1 (de) Imid-derivate, ihre herstellung und verwendung.
FI844333L (fi) 11-substituerade 5h,11h-pyrrolo/2,1-c/ /1,4/benzoxazepiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
NZ221699A (en) Pyridazinone derivatives; pharmaceutical compositions and intermediates
ATE260252T1 (de) Thiocolchicin-derivate mit entzündungshemmender und muskelrelaxierender wirkung
DK0436348T3 (da) Pyridylcyklopropanderivater med fungicid aktivitet
ATE63541T1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
FI941963A (fi) Pyridiinijohdannaiset, niiden valmistus ja käyttö
MX9202994A (es) Derivados de 2-aminoacetamida.
DE69001004D1 (de) Zusammensetzung gegen leberkrankheiten.
ATE218138T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
DE69008130D1 (de) Glutarsäurederivate und ihre Herstellung.
DE69914563D1 (de) Azaindol derivate und ihre Verwendung als antithrombotische Wirkstoffe
ES2058182T3 (es) Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties